Skip to main content

Fiscal Year 2022 Budget

The full Congressional Budget Justification (PDF, 1M) is available in both PDF, and in accessible HTML format below.

Table of Contents

Director’s Overview

Richard Hodes
Dr. Richard J. Hodes, Director

In 2020, approximately 56.4 million Americans were aged 65 and older. This number may rise above 82 million in 2040. This remarkable demographic shift is having and will continue to have profound social and economic impacts on our nation. The National Institute on Aging (NIA) leads the federal government in conducting and supporting research on aging and the health and well-being of older people. We seek to understand the nature of aging and the aging process, and diseases and conditions associated with growing older. Now more than ever, it is critical that we support research on factors throughout the life course that promote healthy aging and research that will enable Americans to maintain healthy, independent, and productive lives throughout life.

Aging itself remains the most important risk factor for many devastating diseases and conditions, including Alzheimer’s disease and related dementias (AD/ADRD), most types of cancer, many types of heart disease, osteoporosis and hip fracture, kidney failure, and diabetes. We are meeting the challenges presented by this demographic shift through our ongoing mission to:

  • Support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging.
  • Foster the development of research and clinician scientists in aging.
  • Provide research resources.
  • Disseminate information about aging and advances in research to the public, health care professionals, and the scientific community, among a variety of audiences.

Since 1974, we have pursued this mission by funding extramural research at universities and medical centers across the United States and around the world; maintaining an active communications and outreach program; and conducting a vibrant intramural research program at NIA laboratories in Baltimore and Bethesda, Maryland. We also support robust training programs to train the next generation of researchers investigating aging. Fundamentally, we support science in service to society. We aim to address public health needs with great urgency, close the gap in health disparities, and capitalize on foundational investments to drive future research and innovation.

Answering the Call: Addressing COVID-19 and Aging Research

The coronavirus disease 2019 (COVID-19) pandemic represents a significant and evolving threat to public health, which has particularly devastating consequences for older adults. Older age represents a primary risk factor for both susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and adverse outcomes from COVID-19, with adults over the age of 65 exhibiting a 23-fold increase in risk of death relative to those under 65. At NIA, we have responded to the urgent need for research on aging and the novel coronavirus to understand and ameliorate the disproportionate impact of the pandemic on older adult populations.

As a first step in addressing the critical need for high-priority research on aging and COVID-19, we issued a special funding opportunity called a Notice of Special Interest (NOSI). Our NOSI is intended to support supplements to existing grant applications on COVID-19-related topics in the realm of neuroscience and AD/ADRD research, aging biology, behavioral and social research, and geriatrics and gerontology. In addition, we issued a funding opportunity for a multi-site COVID-19 clinical trial implementation grant on aging-related topics in at-risk older adult populations. We have also co-sponsored a variety of other National Institutes of Health (NIH) COVID-19-targeted funding opportunities such as those specific to the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) initiative, which is designed to enable and enhance COVID-19 testing in underserved and vulnerable populations, e.g., racial and ethnic minority older adults, residents of nursing homes and assisted living facilities, and individuals with cognitive impairment or dementia.

Our COVID-19 response efforts have yielded an impressive acceleration in research on the novel coronavirus and aging. As of October 2020, we have funded 145 projects on COVID-19, using either our FY 2020 regular appropriations or COVID-19 supplemental appropriations made available through the Office of the Director. Several of these projects have already generated published findings.

For example, NIA-funded investigators have reported that age-related changes can increase COVID-19 susceptibility and severity, including problems with regulation of immune function, widespread inflammation, advanced biological aging, and genetics-related changes.1 NIA-funded researchers are also attending to the social, behavioral, and economic implications of the COVID-19 pandemic and mitigation strategies for the health and well-being of older Americans. This includes a better understanding of increases in COVID-19-associated discrimination and mental distress, particularly among racial and ethnic minorities, and challenges in providing care for vulnerable older adults, particularly those with cognitive impairment, disability, or multiple chronic conditions. These topics represent only a small sample of NIA-supported work currently underway to combat the COVID-19 pandemic, and additional research initiatives are in progress to address this unprecedented crisis.

Understanding the Dynamics of the Aging Process

Aging is associated with changes in dynamic biological, physiological, environmental, psychological, behavioral, and social processes. Some age-related changes are benign, such as graying hair. Others result in declines in function of the senses and activities of daily life, and increased susceptibility to and frequency of disease, frailty, or disability. To develop new interventions for the prevention, early detection, diagnosis, and treatment of aging-related diseases, disorders, and disabilities, we must first understand their causes and the factors that place people at increased risk. NIA-supported researchers are engaged in basic science studies to understand the processes of aging and the factors that determine who ages “well” and who is susceptible to age-related disease and disability. Research is also ongoing to identify the interactions among genetic, environmental, lifestyle, behavioral, and social factors, and their influence on the start and progression of age-related diseases and degenerative conditions.

Aging is the major risk factor for chronic diseases and frailty in people over the age of 55. Geroscience is an evolving field of study specifically aimed at understanding how genetic, molecular, and cellular mechanisms can lead to common chronic conditions and diseases in older adults. Researchers in the field hypothesize that slowing the rate of aging will have a beneficial impact on the health of older adults by delaying the onset or reducing the severity of most chronic diseases and frailty, i.e., improving health at older ages. NIA’s Translational Geroscience Network is transforming our approach to age-related disease and disability by targeting fundamental aging processes in the context of several age-related diseases. In addition, we support clinical trials of interventions for a range of disorders and conditions related to aging, including cardiovascular diseases, osteoporosis, arthritis, cancer, and pain.

Graphic on Geroscience Hypothesis: Aging is malleable, slowing the process of aging, more disease-free years. In the center, a circle lists common chronic diseases, such as COPD, diabetes, asthma, dementia, CVD, and Alzheimer’s. Around the circle is an outer ring labeled aging, surrounded by green arrows that point inward. The arrows depict the potential for geroscience interventions to reduce the impact of chronic diseases by intervening in the aging process.
Green arrows depict the potential for geroscience interventions to reduce the impact of chronic diseases by intervening in the aging process.

A particularly promising avenue of research related to geroscience involves cellular senescence, a process in which cells lose function, including the ability to divide and replicate, but continue to release molecules that damage neighboring cells. NIA-supported investigators found that when treated with senolytics, or compounds that selectively remove senescent cells, mice that had previously been injected with damaging senescent cells regained physical function. Senolytics have also extended the lifespan and healthspan in naturally aging mice.2 In addition, investigators have found that clearing senescent cells from the brain preserves cognition in a mouse model of Alzheimer’s disease.3 Senolytic compounds have recently moved into early-stage human trials supported by NIA. With our involvement, the Cellular Senescence Network was approved in concept in FY 2020 as a Common Fund project by the NIH Council of Councils. The objective of this project is to identify and characterize how different types of senescent cells affect multiple tissues to impact human health, disease, and lifespan.

Additionally, we now know that behavioral and social factors interact with genetic, molecular, and cellular mechanisms to influence health at older ages. We support behavioral science that is uncovering individual-level psychological, social, and behavioral factors throughout the life course that predict adaptive and healthy aging or confer risk for age-related decline. With many chronic conditions emerging in midlife, attention to the interplay of behavioral and social factors with biological processes during this life stage holds potential for identifying optimal time-points for interventions to reverse or redirect aging processes. Evidence suggests that addressing these factors and their interplay will be critical to minimizing disease and achieving full potential and vitality as people age.

Improving the Health, Well-Being, Brain Function, and Independence of Adults as they Age

The brain plays a role in all aspects of thinking — remembering, planning, organizing, making decisions, and much more. These cognitive abilities affect how well we do everyday tasks and whether we can live independently. A better understanding of how the brain ages can provide important information on which to base strategies for maintaining and enhancing cognitive, emotional, sensory, and motor function. Human and animal studies supported by NIA suggest that adaptive or resilient processes (i.e., brain plasticity) may be needed for maintenance of brain structure and function during normal aging. Surprisingly, little is understood about how different areas of the brain connect and work together as a system, yet connectivity is critical to understanding, diagnosing, and treating certain neurological and psychiatric disorders. Problems in connectivity are now suspected in several disorders, including Alzheimer’s disease. We will continue to work to elucidate the processes that occur during “normal” brain aging and to identify and find ways to activate the cellular processes that protect the brain from damage and promote its repair.

We also support and conduct research that is helping to identify lifestyle factors and health behaviors that directly influence physical, cognitive, sensory, and emotional health and risk of disease as people age, such as research linking work and social engagement to cognition. Scientists are developing and refining recommendations for people of all ages regarding optimal diet, use of dietary supplements, mental stimulation, physical exercise, quality sleep, social engagement, stress reduction, and other practices to increase their likelihood of enjoying healthy old age. Still other researchers are looking for better ways to enhance the physical, mental, and social capacities of older adults and to expand opportunities for these individuals to achieve personal goals and continue to contribute to society in meaningful ways. As investigators more precisely identify the psychological, behavioral, and social processes that influence health and quality of life, we will be able to reinforce prevention efforts, enhance symptom management, and conserve function among older adults.

NIA is the lead federal agency for research on AD/ADRD, and our portfolio reflects this important responsibility. In fact, funding for AD/ADRD research has increased so rapidly over the past several years that today, more than half of our awarded grant dollars are dedicated to research on various forms of dementia. These funds support a broad range of projects, including basic molecular and cellular studies of the aging brain; large scale clinical trials of interventions to prevent symptoms of dementia from taking hold; development of a robust infrastructure for drug discovery; and demographic studies of AD/ADRD in different geographic, racial and ethnic, and socioeconomic populations. In order to provide efficacious care for persons living with dementia as well as support for their caregivers, we also fund research on dementia care targeting service access and service quality for persons with dementia, better models of care across care settings with particular interest in care coordination, as well as how regulatory and socio-economic incentives and constraints affect access, quality, and health outcomes for affected individuals.

However, none of this research will ultimately have an impact on public health without sustained efforts to enhance recruitment and retention of participants in our clinical research studies, particularly individuals from diverse backgrounds. To this end, we continue to fund collaborative teams to target gaps in methods and outcomes regarding the challenge of diversity in recruitment. To date, we have funded more than 60 projects submitted in response to a special initiative designed to encourage grant applications for projects that examine health disparities related to AD/ADRD, as well as strategies for recruitment and retention into clinical studies. This funding opportunity will remain active until November 2021, and planning for future initiatives is underway. Topics range from investigating racial and geographic disparities in the risk of AD/ADRD to exploring the effects of participation in long-term community-based trials on lifestyle and risk for Alzheimer’s. We have also awarded a contract that will allow comprehensive management and tracking of clinical research, identify and support sites not able to meet recruitment goals, learn from top-performing sites, and provide transparency regarding recruitment efforts and successes. This contract investment will also enable critical, timely information for ensuring that NIA’s clinical trial sites are making appropriate progress toward reaching recruitment goals related to multiple under-represented groups.

Supporting the AD/ADRD Research Enterprise

A key part of our strategy for developing new treatments for AD/ADRD is to bolster the drug discovery and development pipeline. This strategy helps ensure scientists are addressing these multifaceted diseases through a wide range of approaches. The congressionally targeted increase in funding for AD/ADRD research has enabled us to capitalize on foundational work and enhance investments in key research areas necessary for a precision medicine approach to treatment and prevention. From cutting-edge disease mechanisms and genetics research to population studies and innovative drug and biomarker development programs, we continue to make crucial advancements toward delivering the right treatments to the right people at the right time. Additionally, we have launched several programs over the past six years to provide researchers with an infrastructure for developing their ideas for medicines and other products, including: the Alzheimer’s Disease Sequencing Project, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD), the Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) consortium, and the TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) consortium. A hallmark of these programs is that each one brings together scientists from academia and industry who are working in many different disciplines, from epidemiology and genetics to data science and computational biology, molecular and cell biology, and medicinal chemistry and pharmacology. Working collaboratively, NIA-supported researchers employ an open-science/open-source approach at every step of the translational science process. They are discovering new and better targets for treatment, producing and analyzing comprehensive and shareable sets of molecular data, and developing high quality translational research tools. To date, AMP-AD researchers have identified more than 500 new potential Alzheimer’s drug targets.

With this remarkable foundation in place, recent growth in federal funding for dementia research has enabled us to make additional investments to strengthen the current infrastructure with new, state-of-the-art resources. For example, we are enhancing and expanding the Alzheimer’s Disease Research Centers (ADRCs) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). NIA is particularly active in supporting new and better ways to promote data sharing and reproducibility, provide research resources, and foster public-private partnerships among a broad range of experts and advocates. Already, investigators can more quickly and effectively work with vast amounts of genetic and molecular data to identify new therapeutic drug and nonpharmacological targets and parlay what they learn into the design and testing of potential therapies.

Chevron flow chart: drug discovery to approval. Steps: drug discovery- target ID early validation, assay development & screening; preclinical drug development- proof of concept, lead optimization, candidate selection, toxicology studies; clinical trials- phase 1, 2, & 3 ending at drug approval. NIA-supported candidate drugs in phase 2 trials: LM11A-31, CT1812, BPN14770, & allopregnanolone; MW151 and MW150 in phase 1 trials, developed through a pipeline of public funding opportunities & infrastructure.

 

To accelerate the discovery of effective treatments that will become broadly available to the public, we have developed programs to make data, knowledge, and research tools widely available to all researchers. Complementing the new translational infrastructure is support for new cross-disciplinary training programs funded through NIA’s Institutional Training Programs to Advance Translational Research on AD/ADRD. Through this program, we are supporting a new and more diverse generation of translational scientists with expertise in biology, data science, engineering, and drug development, who are able to participate and lead team-science programs from target discovery to clinical trials. In addition, the NIA-funded Alzheimer’s Clinical Trials Consortium (ACTC), a clinical trials infrastructure to accelerate and expand studies for therapies in AD/ADRD, continues to provide centralized resources and shared expertise to researchers nationwide to hasten the development of effective clinical interventions. In 2020, the ACTC launched the Institute on Methods and Protocols for Advancement of Clinical Trials in AD/ADRD course designed to educate and promote diversity among research professionals and future researchers in the AD/ADRD field.

Overall budget policy: The FY 2022 President’s Budget request for NIA is $4,035.6 million, an increase of $135.7 million or 3.5 percent compared with the FY 2021 Enacted level. This increase will allow NIA to increase research across all its program areas, with a portion of the increase targeted toward research into safer, non-addictive pain therapeutics that will reduce or eliminate the need for opioids.

Back to contents

IC Fact Sheet

Focus of NIA Research

Bar graph that shows NIA appropriations by fiscal year from 2016-2021. Starting on the left and moving to the right the graphs show Dollars, in millions: 2016: ,596; 2017: $2,049; 2018: $2,575; 2019: $3,080; 2020: $3,545; 2021: $3,900. Fiscal year 2022 President’s Budget: $4,035.The National Institute on Aging (NIA) leads the federal government in conducting and supporting research on aging and the health and well-being of older people. NIA is also the lead federal agency for research on Alzheimer’s disease and related dementias (AD/ADRD). NIA supports a strong, diverse, and balanced research program, focusing on the genetics and biology of aging; basic and clinical studies aimed at reducing disease and disability, including AD/ADRD; age-related cognitive change; and investigations of the behavioral and social aspects of aging.

Dr. Richard J. Hodes, Director

Dr. Richard J. HodesRichard J. Hodes, M.D., a leading researcher in the field of immunology, has served as NIA director since 1993. Under Dr. Hodes’ stewardship, the NIA budget has grown to approx. $3.9 billion, reflecting increased public interest in aging research as America and the world grow older.

Current Activities

  • NIA funds a new effort called the Imbedded Pragmatic Alzheimer’s disease and related dementias Clinical Trials (IMPACT) Collaboratory. Through this effort, researchers are developing and testing care interventions in real-world settings.
  • NIA invests in the Alzheimer’s Clinical Trials Consortium (ACTC) to accelerate and expand studies for therapies in AD/ADRD. The goal is to provide an optimized clinical trial infrastructure, utilizing centralized resources and shared expertise, to accelerate the development of interventions.
  • NIA funds a multi-institutional Interventions Testing Program that uses animal models to investigate treatments with the potential to extend lifespan and delay disease and dysfunction.
  • NIA supports the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program. This program fosters the development of clinician-scientists whose clinical research leads to improved care and more effective treatment options for older patients.

Recent Research Accomplishments

Graphic of NIA Research Highlights: Control of a key vascular risk factors can reduce cognitive decline; Moderate calorie restriction lowers heart risk factors; Found more than 50 genetic regions that may increase risk for Alzheimer’s; Improving Care for People with AD/ADRD; Daily low-dose aspirin does not reduce the risk of dementia in older adults who have not had previous CVD events; Repurposed drugs remove senescent cells & extend lifespan in rodents; Biomarkers almost 90% accurate in people with AD.High blood pressure, or hypertension, is very common in people over age 50. It is a leading risk factor for heart disease, stroke, and kidney failure, and a growing body of research suggests that it may increase risk for dementia later in life. In 2019, results from the Systolic Blood Pressure Intervention Trial– Memory and Cognition in Decreased Hypertension (SPRINT-MIND) were the first to show beneficial effects of intensive lowering of high blood pressure for reducing risk of mild cognitive impairment (MCI), a known precursor for dementia. Intensive control was defined as reducing the systolic blood pressure below 120 millimeters of mercury (mmHg), rather than the standard goal of reducing it below 140 mmHg.

Clinical guidelines note the benefits of aspirin for preventing heart attacks and strokes in persons with vascular conditions such as coronary artery disease. There has been, however, past uncertainty about whether aspirin is beneficial for otherwise healthy older people without those conditions. In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (free of dementia or persistent physical disability). Moreover, adverse events were experienced by the group receiving aspirin. This study shows the importance of assessing benefits and risks among healthy older persons.

On the Horizon

  • NIA, in partnership with NINDS, and involving NCATS and the Clinical Center, is establishing a Center for Alzheimer’s and Related Dementias (CARD) in the NIH Intramural Research Program. CARD will combine the power of NIH scientists with the work of researchers around the globe to create new opportunities in basic, translational, and clinical AD/ADRD research and training.
  • NIA is finding new ways to use existing technology for early detection or monitoring of chronic health problems and as part of clinical trials. Technological advances may also assist in early detection and monitoring of AD/ADRD.
  • CDC data show over half of Americans aged 65+ are living with two or more chronic conditions. NIA continues to prioritize research to identify and test interventions that will facilitate optimal management of multiple chronic conditions.

Back to contents

Major Changes in the Fiscal Year 2022 President’s Budget Request

Major changes by budget mechanism and/or budget activity detail are briefly described below. Note that there may be overlap between budget mechanisms and activity detail, and these highlights will not sum to the total change for the FY 2022 President’s Budget request for NIA, which is $4,035.6 million, an increase of $135.7 million from the FY 2021 Enacted level. The FY 2022 President’s Budget reflects the administration’s fiscal policy goals for the federal government. Within that framework, NIA will pursue its highest research priorities through strategic investments and careful stewardship of appropriated funds.

Non-Competing Research Project Grants (+$164.1 million; total $1,817.4 million):
NIA will continue to support its established non-competing Research Project Grants (RPGs) awarding a total of 2,186 RPGs, an increase of 210 from FY 2021. This increase is the result of the increased number of competing RPGs that NIA awarded during previous fiscal years.

Ruth L. Kirschstein Training Awards (+$5.5 million; total $49.4 million):
Support for the Ruth L. Kirschstein Training Awards will increase by $5.5 million to accommodate stipend increases, newly implemented childcare allowances, and increases to other training related expenses. NIA intends to solicit additional training applications to promote diversity in translational research for Alzheimer’s disease and related dementias.

Research & Development Contracts (+$8.8 million; total $138.3 million):
NIA will continue to fund research and development contracts for Alzheimer’s disease and related dementias as well as other projects throughout NIA and the NIH. This increase provides for increased costs in NIA’s existing contracts.

1 doi: 10.18632/aging.103344 (Back to text)

2 doi: 10.1038/s41591-018-0092-9 (Back to text)

3 doi: 10.1038/s41593-019-0372-9 (Back to text)

Back to contents

Budget Mechanism Table* (Dollars in Thousands)
MECHANISM FY 2020 Final Number FY 2020 Final Amount FY 2021 Enacted Number FY 2021 Enacted Amount FY 2022 President's Budget  Number FY 2022 President's Budget  Amount FY 2022 Number +/- FY 2021 Enacted Number FY 2022 Amount +/- FY 2021 Enacted Amount
Research Projects: Noncompeting 1,824 $1,404,513 1,976 $1,653,285 2,186 $1,817,420 210 $164,135
Research Projects: Administrative Supplements  (598) 218,427 (508) 186,247 (317) 115,964 (-191) -70,283
Research Projects, Competing: Renewal 63 102,676 71 102,976 71 102,616 0 -360
Research Projects, Competing: New 1,002 856,159 1,133 858,656 1,128 855,659 -5 -2,997
Research Projects, Competing: Supplements 8 11,467 9 11,500 9 11,460 0 -40
Subtotal, Competing 1,073 $970,302 1,213 $973,132 1,208 $969,735 -5 -$3,397
Subtotal, RPGs 2,897 $2,593,242 3,189 $2,812,664 3,394 $2,903,119 205 $90,455
SBIR/STTR 141 121,365 149 128,641 154 133,001 5 4,360
Research Project Grants 3,038 $2,714,607 3,338 $2,941,305 3,548 $3,036,120 210 $94,815
Research Center: Specialized/Comprehensive 124 $233,961 134 $253,484 141 $265,768 7 $12,284
Research Center: Clinical Research 0 81 0 0 0 0 0 0
Research Center: Biotechnology 0 971 0 1,114 0 0 0 -1,114
Research Center: Comparative Medicine 0 3,047 0 3,437 0 1,402 0 -2,035
Research Centers in Minority Institutions 0 0 0 0 0 0 0 0
Research Centers 124 $238,059 134 $258,035 141 $267,170 7 $9,135
Other Research: Research Careers 375 $59,685 460 $73,143 476 $75,696 16 $2,553
Other Research: Cancer Education 0 0 0 0 0 0 0 0
Other Research Cooperative Clinical Research 0 0 0 0 0 0 0 0
Other Research: Biomedical Research Support 0 0 0 0 0 0 0 0
Other Research: Minority Biomedical Research Support 0 0 0 0 0 0 0 0
Other 128 77,959 185 112,474 189 115,412 4 2,938
Other Research 503 $137,643 645 $185,617 665 $191,108 20 $5,491
Total Research Grants 3,665 $3,090,310 4,117 $3,384,957 4,354 $3,494,398 237 $109,441
Ruth L Kirschstein Training Awards: FTTPs n/a FTTPs n/a FTTPs n/a FTTPs n/a
Individual Awards 189 $8,695 186 $10,329 244 $13,844 58 $3,515
Institutional Awards 487 26,710 526 33,664 515 35,603 -11 1,939
Total Research Training 676 $35,405 712 $43,993 799 $49,447 47 $5,454
Research & Develop. Contracts 54 $108,023 54 $129,477 54 $138,295 0 $8,818
(SBIR/STTR) (non-add) (0) (1,041) (0) (1,154) (0) (1,188) (0) (34)
Intramural Research 235 219,940 248 221,761 260 229,523 12 7,762
Res. Management & Support 203 92,192 230 119,738 260 123,928 30 4,190
SBIR Admin. (non-add) (0) (1,626) (0) (1,997) (0) (2,037) (0) (-1,997)
Construction  0 0   0 0 0 0 0
Buildings and Facilities 0 0   0 0 0 0 0
Total, NIA 438 $3,545,869 478 $3,899,926 520 $4,035,591 42 $135,665

*All items in italics and brackets are non-add entries.

Appropriations Language

For carrying out section 301 and title IV of the PHS Act with respect to aging, [$3,899,227,000] $4,035,591,000.

Back to contents

Summary of Changes (Dollars in Thousands)
FY 2021 Enacted $3,899,926
FY 2022 President's Budget $4,035,591
Net change $135,665
Built-in Changes: Intramural Research FY2021 Enacted: FTEs FY2021 Enacted: Budget Authority FY2022 PB: FTE FY2022 PB: Budget Authority Change from FY 2021: FTEs Change from FY 2021: Budget Authority
a. Annualization of January 2021 pay increase & benefits n/a $51,281 n/a $53,501 n/a $138
b. January FY 2022 pay increase & benefits n/a 51,281 n/a 53,501 n/a 1,390
c. Paid days adjustment n/a 51,281 n/a 53,501 n/a 0
d. Differences attributable to change in FTE n/a 51,281 n/a 53,501 n/a 2,481
e. Payment for centrally furnished services n/a 21,822 n/a 27,033 n/a 5,212
f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs n/a 148,658 n/a 148,989 n/a 4,028
Subtotal n/a n/a n/a n/a n/a $13,250
Built-in Changes: Research Management and Support FY2021 Enacted: FTEs FY2021 Enacted: Budget Authority FY2022 PB: FTE FY2022 PB: Budget Authority Change from FY 2021: FTEs Change from FY 2021: Budget Authority
a. Annualization of January 2021 pay increase & benefits n/a $42,757 n/a $48,693 n/a $113
b. January FY 2022 pay increase & benefits n/a 42,757 n/a 48,693 n/a 1,187
c. Paid days adjustment n/a 42,757 n/a 48,693 n/a 0
d. Differences attributable to change in FTE n/a 42,757 n/a 48,693 n/a 5,577
e. Payment for centrally furnished services n/a 9,018 n/a 14,893 n/a 5,875
f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs n/a 67,963 n/a 60,342 n/a -9,742
Subtotal n/a n/a n/a n/a n/a $3,010
Subtotal, Built-in n/a n/a n/a n/a n/a $16,260
Program Changes FY2021 Enacted # FY2021 Enacted Amount FY 2022 PB # FY 2022 PB Amount Change from FY 2021: Enacted # Change from FY 2021: Enacted Amount
1. Research Project Grants: a. Noncompeting 1,976 $1,839,532 2,186 $1,933,384 210 $93,852
1. Research Project Grants: b. Competing 1,213 973,132 1,208 969,735 -5 -3,397
1. Research Project Grants: c. SBIR/STTR 149 128,641 154 133,001 5 4,360
Subtotal, RPGs 3,338 $2,941,305 3,548 $3,036,120 210 $94,815
2. Research Centers 134 $258,035 141 $267,170 7 $9,135
3. Other Research 645 185,617 665 191,108 20 5,491
4. Research Training 712 43,993 759 49,447 47 5,454
5. Research and development contracts 54 129,477 54 138,295 0 8,818
Subtotal, Extramural n/a $3,558,427 n/a $3,682,140 n/a $123,713
Program Changes FY2021 Enacted #: FTEs FY2021 Enacted Amount FY2022 PB #: FTEs FY 2022 PB Amount Change from FY 2021: FTEs Change from FY 2021: Enacted Amount
6. Intramural Research 248 $221,761 260 $229,523 12 -$5,488
7. Research Management and Support 230 119,738 260 123,928 30 1,180
8. Construction n/a 0 n/a 0 n/a 0
9. Buildings and Facilities n/a 0 n/a 0 n/a 0
Subtotal, Program 478 $3,899,926 520 $4,035,591 42 $119,405
Total built-in and program changes n/a n/a n/a n/a n/a $135,665

Back to contents

Fiscal Year 2022 Budget Graphs

History of Budget Authority and FTEs:

A bar graph depicting funding levels by fiscal year in millions between 2018 and 2022. 2018, $2,571.5; 2019, $3,080; 2020, $3,545.9; 2021 $3,899.9 and in 2022 $,4,035.6.A bar graph depicting FTEs by Fiscal Year between 2018 and 2022. 2018, 416; 2019 417; 2020, 438; 2021 478; and in 2022 520. : $2,049; 2018: $2,575; 2019: $3,080; 2020: $3,545; 2021: $3,900. Fiscal year 2022 President’s Budget: $4,035.

Distribution by Mechanism:

Pie chart showing FY 2022 Budget Mechanisms (Dollars in Thousands). The largest is Research Project Grants at $3,036,120 at 75%, reading clockwise is followed by Research Training $49,447 at 1%. RMS $123,928 at 3%. Intramural Research is $229,523 at 6%. Other Research is $191,108 at 5%. R&D Contracts is $138,295 at 3% and Research Centers is $267,170 at 7%.

Change by Selected Mechanism:

Bar chart showing FY 2022 estimated percent change from FY 2021 Mechanism. Research Project Grants is 3.22%. Research Centers is 3.54%, Other Research is 2.96%. Research Training is 12.40%. R&D Contracts is 6.81%. Intramural Research is 3.50% and Research Management and Support is 3.50%.

Back to contents

Organizational Chart

Organizational Structure diagram: Office of the Director, Dr. Richard J. Hodes, Director, and Dr. Marie A. Bernard, Deputy Director. All the following departments report directly to the Office of the Director, in the following rows. First row: Intramural Research Program, Dr. Luigi Ferrucci, Director; Office of Administrative Management, Mr. Patrick Shirdon, Director of Management. Second row: Division of Extramural Activities, Dr. Kenneth Santora, Director. Third row Division of Aging Biology, Dr. Ronald A Kohanski, Director; Division of Geriatrics and Clinical Gerontology, Dr. Evan Hadley, Director; Division of Behavioral and Social Research, Dr. Lisbeth Nielson, Director; Division of Neuroscience, Dr. Eliezer Masliah, Director.

 

Back to contents

Budget Authority by Activity
Extramural Research FY 2020 Final FTE FY 2020 Final Amount FY 2021 Enacted FTE FY 2021 Enacted Amount FY 2022 PB FTE FY 2022 PB Amount FY 2022 +/- FY 2021 Enacted FTE FY 2022 +/- FY 2021 Enacted Amount
Aging Biology N/A $341,748 N/A $376,062 N/A $389,136 N/A $13,074
Behavioral & Social Research N/A 519,251 N/A 571,387 N/A 591,252 N/A 19,865
Neuroscience N/A 2,072,598 N/A 2,280,702 N/A 2,359,994 N/A 79,292
Geriatrics & Clinical Gerontology N/A 300,140 N/A 330,276 N/A 341,758 N/A 11,482
Subtotal, Extramural N/A $3,233,737 N/A $3,558,427 N/A $3,682,140 N/A $123,713
Intramural Research 235 $219,940 248 $221,761 260 $229,523 12 $7,762
Research Management & Support 203 $92,192 230 $119,738 260 $123,928 30 $4,190
TOTAL 438 $3,545,869 478 $3,899,926 520 $4,035,591 42 $135,665

Justification of Budget Request

Authorizing Legislation

Section 301 and title IV of the Public Health Service Act, as amended.

Budget Authority (BA)
Category FY 2020 Final FY 2021 Enacted FY 2022 President's Budget FY 2022 +/- FY 2021
BA $3,545,869,000 $3,899,926,000 $4,035,591,000 +$135,665,000
FTE 438 478 520 42

Program funds are allocated as follows: Competitive Grants/Cooperative Agreements; Contracts; Direct Federal/Intramural and Other.

Back to contents

Program Descriptions

Division of Aging Biology

Aging is a primary risk factor for many diseases and frailties. The NIA Division of Aging Biology (DAB) supports research to determine the basic biochemical and genetic mechanisms underlying the processes of aging at the cell, tissue, and organ levels, and the ways these changes are communicated among cells and tissues of the body. DAB-supported investigators study the changes in molecular and cellular structures and functions that characterize normal aging in diverse laboratory organisms, spanning yeast to nonhuman primates, and where the opportunities arise, in humans. The division also supports research on the mechanisms and interventions that increase or decrease the rate of aging, including in natural human variants such as people with progeroid syndromes, who display signs of premature physical aging, and centenarians (or their laboratory equivalents). Importantly, DAB is initiating programs into the basic biology of aging in disadvantaged and minority populations.

DAB also coordinates the groundbreaking trans-NIH GeroScience Interest Group (GSIG). Using the hypothesis that slowing the rate of aging-related biological changes will have a beneficial impact on many health outcomes, GSIG promotes studies into the interactions among the biology of aging and the biology of diseases and age-related loss of resilience. Most NIH Institutes and Centers participate in the GSIG, engaging in outreach to scientific societies, the pharmaceutical industry, and experts in emerging biotechnology. The GSIG has held three summits — the most recent of which was in November 2019 — to generate scientific ideas and momentum in the field.

DAB-supported researchers have made important discoveries in exercise, dietary regimens, and other interventions that affect aging in laboratory animals, with potential for translation into practical ways of improving health in humans. DAB supports the Intervention Testing Program (in mice) and the Caenorhabditis Intervention Testing Program (in roundworms). Through both programs, scientists test the effectiveness and reproducibility of interventions — including foods, hormones, and pharmaceuticals — on extending lifespan and enhancing functions at older ages. To date, 43 compounds have been tested, 7 with a positive effect on at least one sex. Both programs foster collaborations to identify the mechanisms by which these compounds extend life and improve health. NIA-supported investigators are now studying some of these interventions (and others, as scientifically appropriate) in models of AD/ADRD to determine their effects on the diseases’ pathogenesis and progression.

DAB also supports the Nathan Shock Centers of Excellence, which provide national leadership and research resources in the basic biology of aging. In FY 2020, in addition to the renewal of six previously funded Shock Centers, NIA awarded two new centers. DAB also supports selected resources for biology of aging research, including colonies of aging rodents, collections of cells derived from rodent, non-human primate and human longitudinal studies of aging, and from individuals affected by premature aging disorders. All these programs will remain active in FY 2022.

Budget Policy: The FY 2022 President’s Budget request is $389.1 million, an increase of $13.1 million or 3.5 percent compared to the FY 2021 Enacted level.

Division of Behavioral and Social Research

The NIA Division of Behavioral and Social Research (DBSR) supports research at all levels - from basic to translational - designed to elucidate the pathways by which social, psychological, economic, and behavioral factors throughout the life course affect health at older ages, identify the causal mechanisms that account for observed associations, and ultimately target these mechanisms to modify individual behaviors and social contexts to promote health and prevent disease. DBSR’s portfolio is broad and spans topics ranging from the genetics of age-related behavior change to sweeping demographic studies with a global reach. DBSR also supports numerous transdisciplinary research networks designed to develop the infrastructure and research capacity to address these challenges.

DBSR recently renewed funding for the trans-NIH Science of Behavior Change program, working with other NIH Institutes, Centers, and Offices to capitalize on emerging basic science and the success of existing evidence-based behavior change interventions to accelerate investigation of common mechanisms of behavior change applicable across a broad range of health behaviors.

Notably, DBSR supports the Health and Retirement Study (HRS), the nation's leading source of combined data on health and socioeconomic circumstances of Americans over age 50. Researchers have used HRS data to calculate life expectancy and disability trends and to estimate the costs, both to the individual and to society, of age-related diseases and conditions. In 2018, the HRS implemented a Harmonized Cognitive Assessment Protocol to measure and understand dementia risk, designed to be comparable with similar assessments in international HRS comparator studies around the world. This tool provides the research community with rich data to study the prevalence, predictors, outcomes and future trends in cognitive functioning and dementia on a global scale. DBSR supports other longitudinal studies focusing on trends in late life disability and caregiving (National Health and Aging Trends Study) and on the influences of behavioral, psychological, and social factors in midlife on age-related variations in health and well-being (Midlife in the United States Study). The division also coordinates several active centers programs. Centers on the Demography and Economics of Aging were renewed in FY 2020, with the addition of new Centers on Demography and Economics of Alzheimer’s Disease and Related Dementias. The Edward R. Roybal Centers for Translational Research on Aging were renewed and expanded in FY 2019 (see program portrait on AD/ADRD Care and Caregiving), and the Resource Centers for Minority Aging Research (RCMARs) continue their program of mentoring and research in priority areas of social, behavioral, and economic research on the processes of aging at the individual and societal levels.

Budget Policy: The FY 2022 President’s Budget request is $591.3 million, an increase of $19.9 million or 3.5 percent compared to the FY 2021 Enacted level.

Division of Geriatrics and Clinical Gerontology

The Division of Geriatrics and Clinical Gerontology (DGCG) promotes clinical and translational research on health and disease in older adults, as well as research on aging over the human life span. In particular, DGCG supports clinical trials on the effectiveness of interventions in clinical settings, translational research for the development of new interventions for age-related conditions, prevention and treatment of multiple chronic conditions in older individuals, and studies that help to promote evidence-based geriatric care that inform policies affecting this group.

DGCG-supported research encompasses a range of age-related diseases and conditions, including AD/ADRD. For example, in 2019 DGCG funded a Phase 4 drug study called Pragmatic Evaluation of Events and Benefits of Lipid-Lowering in Older Adults (PREVENTABLE). Through this Phase 4 trial, researchers are examining the overall benefits and risks of the commercially available cholesterol-lowering drug atorvastatin in 20,000 adults age 75 or older without cardiovascular disease. The trial will help determine whether the drug can help prevent dementia and disability in this age group, as well as prevent heart attacks and other cardiovascular-related deaths, without increasing adverse health outcomes.

Another DGCG-administered initiative set for FY 2022 will support the development of a collaborative research and resource network to address research gaps toward optimizing recognition and emergency care of older adults with AD/ADRD. The focus will be on those who may be particularly vulnerable in emergency care settings to misdiagnosis, inappropriate tests or treatments, inability to provide informed consent to treatment, and unsafe discharge.

DGCG also supports research on multifactorial geriatric syndromes such as falls, frailty, and various types of disability; determinants of rates of progression of age-related changes that affect disease risk; and complications of multiple ailments. Recent DGCG funding opportunity announcements (FOAs) have solicited applications on palliative care, aging in older persons with HIV/AIDS, and possible effects of the commonly prescribed diabetes drug metformin on the aging process. Studies supported through these FOAs will be active in FY 2022.

DGCG invests in studies on persons and families who maintain health into very old age, to find factors that contribute to long “healthspan.” These studies have identified genetic and other factors that may provide a basis for new interventions to promote long healthy life.

DGCG also supports the Claude D. Pepper Older Americans Independence Centers Program, which supports research to identify effective methods to maintain or restore independence in older adults. Funding for this important program was renewed in FY 2018, and the centers will be active in FY 2022. As part of its renewal, this program was expanded to include up to three additional Centers. Currently there are 14 fully funded Pepper Centers. In addition, this division provides critical research resources to the scientific community, including the Aging Research BioBank, a unique platform for sharing data and biospecimens, and a web-based “toolbox” for NIH-supported investigators and staff involved in clinical research.

Budget Policy: The FY 2022 President’s Budget request is $341.8 million, an increase of $11.5 million or 3.5 percent compared to the FY 2021 Enacted level.

Division of Neuroscience

NIA’s Division of Neuroscience (DN) supports basic, clinical, and epidemiologic research and training to further our understanding of both normal and pathological age-related changes to the nervous system and the influence of these changes on cognition and behavior. DN also supports basic and clinical research aimed at maintaining or improving sleep, sensory and motor function with age, and studies exploring alterations in blood flow in the brain as a possible contributor to gait dysfunction and falls. A primary focus is research on AD/ADRD, in support of the goal articulated in the National Plan to Address AD/ADRD, of effectively treating or preventing these diseases by 2025. The division supports studies to understand AD/ADRD’s molecular, cellular, and genetic underpinnings; biomarker discovery and validation; epidemiological studies to establish prevalence and incidence estimates and identify risk and resilience factors; and drug discovery, development, and testing. DN also supports the work of researchers investigating the interaction between Alzheimer’s and Down syndrome.

In recent years, NIA has received generous support targeted to AD/ADRD and these funds have facilitated significant progress in the field. Ongoing and recent research initiatives include developing new biomarkers for AD/ADRD, investigation of sex differences in AD/ADRD, understanding senescence in brain aging and AD/ADRD, clarifying the relationship between delirium and AD/ADRD, and common mechanisms and interactions among neurodegenerative diseases.

NIA supports a national network of 35 AD Research Centers (ADRCs) that work to translate research discoveries into AD diagnostics and drug treatment interventions, as well as executing a wide range of studies to enhance understanding of AD/ADRD. These centers are funded via a competitive review process. In FY 2020, the centers program expanded with the launch of four “Exploratory ADRCs.” These new centers will further incentivize innovative ideas and opportunities in AD/ADRD research and support institutions as they initiate collaborative activities to develop and implement infrastructure appropriate for the larger ADRC program.

Budget Policy: The FY 2022 President’s Budget request is $2,360.0 million, an increase of $79.3 million or 3.5 percent compared to the FY 2021 Enacted level.

Intramural Research Program

Through its Intramural Research Program (IRP), NIA supports basic, behavioral, clinical, epidemiologic, and translational research with the goal of understanding the physiological changes and adaptability of the human body in response to age and stress. Knowledge about the biology of aging and chronic disease is necessary to develop new effective interventions that reduce the burden of disease and disability in the older population, and IRP investigators use this understanding to clarify the pathophysiology of age-related diseases and help create new therapeutics and interventions for these conditions. While IRP’s eight laboratories and one center each focuses on specific areas of research, they share the common goal of expanding our knowledge of the aging process and age-related disease and collaborate in these efforts.

IRP investigators conduct research in three main focus areas: aging biology, neuroscience, and translational gerontology. Specific areas of interest include 1) epidemiologic research; 2) behavioral research; 3) genetics and genomics; 4) clinical and translational research; and 5) neuroscience and neurogenetics. Age-associated diseases that are priority areas of research include AD/ADRD, Parkinson’s disease, diabetes, cardiovascular diseases, stroke, osteoporosis and osteoarthritis, autoimmune diseases such as multiple sclerosis and lupus, and cancers.

In 2019, NIA launched the collaborative intramural Center for Alzheimer’s and Related Dementias (CARD) in partnership with the National Institute of Neurological Disorders and Stroke, and also including the National Center for Advancing Translational Sciences, and the NIH Clinical Center. CARD will be housed in the newly constructed headquarters on the NIH main campus in Bethesda, Maryland. The center will combine the power of NIH intramural science with the work of researchers around the globe to push boldly ahead in basic, translational, and clinical AD/ADRD research.

Additionally, IRP’s longitudinal cohort studies have contributed greatly to aging research. Prominent studies include the trailblazing Baltimore Longitudinal Study of Aging (BLSA), which explores the determinants and measures of healthy biological aging over time and is the nation’s longest running scientific study of human aging; the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study, which researches the impact of racial and socioeconomic diversity on health disparities and healthy aging; and the Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT) study, which is aimed at discovering biomarkers and their connections to aging.

IRP also supports training programs for students and recent graduates that give young scientists the opportunity to learn skills in basic and clinical aging research in the biomedical and behavioral sciences. This may help combat the nation’s unmet need for researchers and clinician-scientists to focus on aging-related research issues.

Budget Policy: The FY 2022 President’s Budget request is $229.5 million, an increase of $7.8 million or 3.5 percent compared to the FY 2021 Enacted level.

Research Management and Support

NIA Research Management Support (RMS) activities provide administrative, budgetary, logistical, and scientific support in the review, award, and monitoring of research grants, and research and development contracts. RMS functions also encompass communications, strategic planning, coordination, and evaluation of the Institute's programs, regulatory compliance, international coordination, and liaison with other Federal agencies, Congress, and the public. In FY 2020, the Institute monitored 3,665 research grants as well as 676 full-time training positions and 54 research and support contracts.

Budget Policy: The FY 2022 President’s Budget request is $123.9 million, an increase of $4.2 million or 3.5 percent compared to the FY 2021 Enacted level.

Back to contents

Appropriations History
Fiscal Year Budget Estimate to Congress House Allowance Senate Allowance Appropriation
2013 $1,102,650,000 n/a $1,124,265,000 $1,103,440,548
2013 Rescission n/a n/a n/a $2,206,881
2013 Sequestration n/a n/a n/a ($55,385,128)
2014 $1,193,370,000 n/a $1,185,439,000 $1,171,038,000
2014 Rescission n/a n/a n/a $0
2015 $1,170,880,000 n/a n/a $1,199,468,000
2015 Rescission n/a n/a n/a $0
2016 $1,267,078,000 $1,518,421,000 $1,548,494,000 $1,600,191,000
2016 Rescission n/a n/a n/a $0
2017* $1,598,246,000 $1,982,102,000 $2,067,138,000 $2,048,610,000
2017 Rescission n/a n/a n/a $0
2018 $1,303,541,000 $2,458,733,000 $2,535,539,000 $2,574,091,000
2018 Rescission n/a n/a n/a $0
2019 $1,988,200,000 $3,005,831,000 $3,084,809,000 $3,083,410,000
2019 Rescission n/a n/a n/a $0
2020 $2,654,144,000 $3,356,107,000 $3,606,040,000 $3,543,673,000
2020 Rescission n/a n/a n/a $0
2021 $3,225,782,000 $3,609,150,000 $4,015,333,000 $3,899,227,000
2021 Rescission n/a n/a n/a $0
2022 $4,035,591,000 n/a n/a n/a

*Budget Estimate to Congress includes mandatory financing.

Back to contents

Authorizing Legislation
Category PHS Act/ Other Citation U.S. Code Citation 2021 Amount Authorized FY 2021 Enacted 2022 Amount Authorized FY 2022 President's Budget
Research and Investigation Section 301 42§241 Indefinite $3,899,926,000 Indefinite $4,035,591,000
National Institute on Aging Section 401(a) 42§281 Indefinite $3,899,926,000 Indefinite $4,035,591,000
Total, Budget Authority n/a n/a n/a $3,899,926,000 n/a $4,035,591,000
Amounts Available for Obligation* (Dollars in Thousands)
Source of Funding FY 2020 Final FY 2021 Enacted FY 2022 President's Budget
Appropriation $3,543,673 $3,899,227 $4,035,591
Secretary's Transfer  0 0 0
OAR HIV/AIDS Transfers 2,196 699 0
Subtotal, adjusted budget authority $3,545,869 $3,899,926 $4,035,591
Unobligated balance, start of year 0 0 0
Unobligated balance, end of year 0 0 0
Subtotal, adjusted  budget authority $3,545,869 $3,899,926 $4,035,591
Unobligated balance lapsing -55 0 0
Total obligations $3,545,814 $3,899,926 $4,035,591

*Excludes the following amounts (in thousands) for reimbursable activities carried out by this account:

  • FY 2020 - $7,866
  • FY 2021 - $20,000
  • FY 2022 - $20,000

Back to contents

Budget Authority by Object Class* (Dollars in Thousands)
Total compensable workyears: FY 2021 Enacted FY 2022 President's Budget FY 2022 +/- FY 2021 Enacted
Full-time equivalent 478 520 42
Full-time equivalent of overtime and holiday hours 0 0 0
Average ES salary $199 $201 $2
Average GM/GS grade 12.3 12.4 0.0
Average GM/GS salary $115 $118 $3
Average salary, Commissioned Corps (42 U.S.C. 207) $106 $109 $3
Average salary of ungraded positions $171 $180 $9
OBJECT CLASSES FY 2021 Enacted FY 2022 President's Budget FY 2022 +/- FY 2021
Personnel Compensation n/a n/a n/a
11.1 Full-Time Permanent 43,426 48,420 4,994
11.3 Other Than Full-Time Permanent 16,421 16,795 374
11.5 Other Personnel Compensation 1,611 1,648 37
11.7 Military Personnel 359 369 10
11.8 Special Personnel Services Payments 9,281 9,492 211
11.9 Subtotal Personnel Compensation $71,098 $76,724 $5,625
12.1 Civilian Personnel Benefits 22,626 25,147 2,522
12.2 Military Personnel Benefits 314 323 9
13.0 Benefits to Former Personnel 0 0 0
Subtotal Pay Costs $94,038 $102,194 $8,156
21.0 Travel & Transportation of Persons 593 604 11
22.0 Transportation of Things 334 340 6
23.1 Rental Payments to GSA 223 227 4
23.2 Rental Payments to Others 9 9 0
23.3 Communications, Utilities & Misc. Charges 5,546 5,670 125
24.0 Printing & Reproduction 0 0 0
25.1 Consulting Services 45,782 57,137 11,355
25.2 Other Services 47,541 45,926 -1,615
25.3 Purchase of goods and services from government accounts 191,123 200,324 9,201
25.4 Operation & Maintenance of Facilities 3,675 3,677 2
25.5 R&D Contracts 26,700 27,180 481
25.6 Medical Care 9,607 9,963 355
25.7 Operation & Maintenance of Equipment 3,650 3,716 65
25.8 Subsistence & Support of Persons 0 0 0
25.0 Subtotal Other Contractual Services $328,078 $347,922 $19,845
26.0 Supplies & Materials 15,322 15,598 276
31.0 Equipment 17,329 17,641 312
32.0 Land and Structures 46,985 36,568 -10,417
33.0 Investments & Loans 0 0 0
41.0 Grants, Subsidies & Contributions 3,391,468 3,508,817 117,348
42.0 Insurance Claims & Indemnities 0 0 0
43.0 Interest & Dividends 0 0 0
44.0 Refunds 0 0 0
Subtotal Non-Pay Costs $3,805,888 $3,933,397 $127,509
Total Budget Authority by Object Class $3,899,926 $4,035,591 $135,665

*Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

Back to contents

Salaries and Expenses (Dollar in Thousands)
OBJECT CLASSES FY 2021 Enacted FY 2022 President's Budget FY 2022 +/- FY 2021
Personnel Compensation n/a n/a n/a
Full-Time Permanent (11.1) $43,426 $48,420 $4,994
Other Than Full-Time Permanent (11.3) 16,421 16,795 374
Other Personnel Compensation (11.5) 1,611 1,648 37
Military Personnel (11.7) 359 369 10
Special Personnel Services Payments (11.8) 9,281 9,492 211
Subtotal Personnel Compensation (11.9) $71,098 $76,724 $5,625
Civilian Personnel Benefits (12.1) $22,626 $25,147 $2,522
Military Personnel Benefits (12.2) 314 323 9
Benefits to Former Personnel (13.0) 0 0 0
Subtotal Pay Costs $94,038 $102,194 $8,156
Travel & Transportation of Persons (21.0) $593 $604 $11
Transportation of Things (22.0) 334 340 6
Rental Payments to Others (23.2) 9 9 0
Communications, Utilities & Misc. Charges (23.3) 5,546 5,670 125
Printing & Reproduction (24.0) 0 0 0
Other Contractual Services: n/a n/a n/a
Consultation Services (25.1) 45,782 57,137 11,355
Other Services (25.2) 47,541 45,926 -1,615
Purchases from government accounts (25.3) 93,135 98,927 5,792
Operation & Maintenance of Facilities (25.4) 3,675 3,677 2
Operation & Maintenance of Equipment (25.7) 3,650 3,716 65
Subsistence & Support of Persons (25.8) 0 0 0
Subtotal Other Contractual Services $193,783 $209,383 $15,600
Supplies & Materials (26.0) $15,322 $15,598 $276
Subtotal Non-Pay Costs $215,587 $231,604 $16,017
Total Administrative Costs $309,625 $333,798 $24,173
Detail of Full-Time Equivalent Employment (FTE)
OFFICE/DIVISION FY 2020 Final: Civilian FY 2020 Final: Military FY 2020 Final: Total FY 2021 Enacted: Civilian FY 2021 Enacted: Military FY 2021 Enacted: Total FY 2022 PB: Civilian FY 2022 PB: Military FY 2022 PB: Total
Division of Aging Biology (Direct): 15 - 15 18 - 18 21 - 21
Division of Aging Biology (Reimbursable): - - - - - - - - -
Division of Aging Biology Total: 15 - 15 18 - 18 21 - 21
Division of Behavioral & Social Research (Direct): 19 - 19 25 - 25 30 - 30
Division of Behavioral & Social Research (Reimbursable): - - - - - - - - -
Division of Behavioral & Social Research Total: 19 - 19 25 - 25 30 - 30
Division of Extramural Affairs (Direct): 49 - 49 52 - 52 55 - 55
Division of Extramural Affairs (Reimbursable): - - - - - - - - -
Division of Extramural Affairs Total: 49 - 49 52 - 52 55 - 55
Division of Geriatrics & Clinical Gerontology (Direct): 15 - 15 17 - 17 20 - 20
Division of Geriatrics & Clinical Gerontology (Reimbursable): - - - - - - - - -
Division of Geriatrics & Clinical Gerontology (Total): 15 - 15 17 - 17 20 - 20
Division of Neuroscience (Direct): 37 - 37 46 - 46 56 - 56
Division of Neuroscience (Reimbursable): - - - - - - - - -
Division of Neuroscience Total: 37 - 37 46 - 46 56 - 56
Intramural Research Program (Direct): 233 2 235 247 1 248 259 1 260
Intramural Research Program (Reimbursable): - - - - - - - - -
Intramural Research Program Total: 233 2 235 247 1 248 259 1 260
Office of Administrative Management (Direct): 43 - 43 45 - 45 49 - 49
Office of Administrative Management (Reimbursable): - - - - - - - - -
Office of Administrative Management Total: 43 - 43 45 - 45 49 - 49
Office of the Director (Direct): 25 - 25 27 - 27 29 - 29
Office of the Director (Reimbursable): - - - - - - - - -
Office of the Director Total: 25 - 25 27 - 27 29 - 29
Total* 436 2 438 477 1 478 519 1 520
FTEs supported by funds from Cooperative Research and Development Agreements. 0 0 0 0 0 0 0 0 0

*FTEs supported by funds from Cooperative Research and Development Agreements.

FISCAL YEAR Average GS Grade
2018 12.1
2019 12.2
2020 12.3
2021 12.3
2022 12.4
Back to contents
Detail of Positions*
GRADE FY 2020 Final FY 2021 Enacted FY 2022 President's Budget
Total, ES Positions 1 1 1
Total, ES Salary 197,300 199,300 201,300
General Schedule n/a n/a n/a
GM/GS-15 54 60 65
GM/GS-14 61 75 80
GM/GS-13 96 100 120
GS-12 62 65 70
GS-11 31 43 50
GS-10 0 0 0
GS-9 34 34 34
GS-8 3 3 3
GS-7 19 19 19
GS-6 2 2 2
GS-5 3 3 3
GS-4 2 2 2
GS-3 0 0 0
GS-2 0 0 0
GS-1 0 0 0
Subtotal 367 406 448
Commissioned Corps (42 U.S.C. 207) n/a n/a n/a
Assistant Surgeon General 0 0 0
Director Grade 1 1 1
Senior Grade 0 0 0
Full Grade 0 0 0
Senior Assistant Grade 0 0 0
Assistant Grade 0 0 0
Subtotal 1 1 1
Ungraded 113 115 117
Total permanent positions 366 406 448
Total positions, end of year 482 523 567
Total full-time equivalent (FTE) employment, end of year 438 478 520
Average ES salary 197,300 199,300 201,300
Average GM/GS grade 12.3 12.3 12.4
Average GM/GS salary 114,694 115,477 118,102

*Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

Back to contents